SSG
CRMD icon

Summit Securities Group’s CorMedix CRMD Stock Holding History

Summit Securities Group’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,256
Closed -$69.6K – 1198
2026
Q1 		$69.6K Buy
+10,256
New +$75.8K 0.01% 332
2025
Q4 		– Sell
-463
Closed -$5.38K – 1058
2025
Q3 		$5.38K Sell
463
-2,128
-82% -$25.7K ﹤0.01% 918
2025
Q2 		$31.9K Buy
+2,591
New +$28.6K 0.01% 613

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Summit Securities Group's CRMD Position: Q2 2026 in Review

Summit Securities Group sold out of CorMedix (CRMD) in Q2 2026, closing a stake of 10,256 shares — an estimated $69.6K sold.

Summit Securities Group first reported a position in CRMD in Q2 2025 and held it in 3 quarters. The position peaked at $69.6K in Q1 2026. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Summit Securities Group reported no remaining CorMedix position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 10,256 CorMedix shares in Q2 2026, an estimated $69.6K.
  • Summit Securities Group first reported a position in CorMedix in Q2 2025 and held it in 3 quarters.
  • Summit Securities Group's CorMedix position peaked at $69.6K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.